Our clinical team led by Gain’s Chief Medical Officer, Jonas Hannestad, is currently working closely with seven clinical centers in Australia to begin dosing the first patients in the Phase 1b clinical trial, which we expect to happen imminently. We expect to provide an enrollment update by the end of https://www.forex-world.net/ 1Q 2025 and guidance in 2Q 2025 when we expect to be in position to discuss interim analysis of the Phase 1b clinical trial. Private equity firms hold a 13% stake in Microvast Holdings. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
- Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature.
- Of course, keep in mind that there are other factors to consider, too.
- It has a market capitalization of just US$638m, and insiders have US$188m worth of shares in their own names.
- Building on the accomplishments and dedicated work of the entire Gain team in 2024, we continue to advance the clinical development of GT-02287, a potentially disease-modifying therapy for Parkinson’s disease (PD) in people with or without a GBA1 mutation.
- However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
SHAREHOLDER ALERT: WeissLaw LLP Reminds GCAP and MYOS Shareholders About Its Ongoing Investigations
Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab). Part of StoneX Group, Inc., StoneX Financial Pty Ltd. is an Australian company that distributes electronic goods related to stock trading. Sean Michael O’Connor has been the CEO of the company since 2002. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
Business Summary
While this group can’t necessarily call the shots, it can certainly have a real influence on how the company is run. Retail investors gained the most after market cap touched US$638m last week, while insiders who own 29% also benefitted. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function.
Exchange Traded Funds Etf company, deterioration in the corporate behavior throughout the fiscal first quarter of 2025
Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. I generally consider insider ownership to be a good thing.
- Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
- Parkinson’s disease remains the second most common neurodegenerative disease after Alzheimer’s and yet there are only symptomatic treatments available to patients.
- Gain’s lead drug candidate, GT is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation.
- We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business.
- Our information suggests that insiders maintain a significant holding in Microvast Holdings, Inc..
- While there is some analyst coverage, the company is probably not widely covered.
It provides services to retail customers through FOREX.com and Cityindex.com, as well as through brokers and white label partners. The company offers execution and risk management services for exchange-traded futures and futures options on the United States and European futures and options exchanges; and online trading services. GAIN Capital Holdings, Inc. was founded in 1999 and is headquartered in Bedminster, New Jersey. Institutional foreign exchange, trading and related services providing direct access paxful review to the global OTC foreign exchange markets, where participants trade directly with one another. Its trading platforms provide information and analytical tools that allow customers to identify, analyze and execute their trading strategies. GAIN also offers retail customers located outside the United States access to other global markets on an OTC basis, including the spot gold and silver markets, as well as equity indices and commodities.
I’m inspired by the dedication of our team and grateful to share this important mission with you. I look forward to keeping you updated as we progress through the year and thank you for your support along the way. As a reminder, we are planning on enrolling individuals with either GBA1 or idiopathic Parkinson’s disease – all of whom will receive oral GT daily for three months in the open-label Phase 1b clinical trial. We plan to evaluate different biomarkers of Parkinson’s disease from the cerebrospinal fluid and plasma samples taken from participants at baseline and completion of the study. The Barchart Technical Opinion widget shows you today’s overall Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
Investment Banking & Brokerage Services
Enter your email address and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Provides a general description of the business conducted by this company.
It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Microvast Holdings, (below). Of course, keep in mind that there are other factors to consider, too. In 2025, we will remain focused on strengthening our collaboration with the FDA and other regulatory authorities to expand the clinical development of GT within the U.S. In early December 2024, we held a Forex fibonachi productive pre-IND meeting with the FDA and received encouraging feedback that aligned with our expectations. Notably, the FDA did not identify any significant regulatory hurdles that could delay our preparations for Phase 2.
Instrument NameGain Capital HoldingsInstrument Symbol(GCAP-N)Instrument ExchangeNYSE
Part of StoneX Group, Inc., GTX SEF LLC is a company that provides online foreign exchange trading services. With 2025 poised to be another pivotal year for Gain Therapeutics, I want to take a moment to provide an update on the key milestones we are expecting to achieve in 2025. Building on the accomplishments and dedicated work of the entire Gain team in 2024, we continue to advance the clinical development of GT-02287, a potentially disease-modifying therapy for Parkinson’s disease (PD) in people with or without a GBA1 mutation. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered.
We believe this progress derisks our upcoming IND submission and offers flexibility to potentially expand our current Phase 1b trial. We look forward to ongoing engagement with the FDA as we advance these critical efforts and will leverage the experience of our newly formed Clinical Advisory Board as needed. In December 2024, we received approval to initiate our Phase 1b clinical trial of GT in people with GBA1 or idiopathic Parkinson’s disease.
GAIN Capital Holdings, Inc., together with its subsidiary, provides trading services and solutions to retail, institutional, and futures service customers worldwide. The company operates in two segments, Retail and Futures. It specializes in over-the-counter (OTC) and exchange-traded markets.